title: Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice.
abstract: By employing modified Cornell model, we have evaluated the potential of adjunctive immunotherapy with DNA vaccines to shorten the tuberculosis chemotherapy period and reduce disease reactivation. We demonstrate that α-crystallin based DNA vaccine (DNAacr) significantly reduced the chemotherapy period from 12 weeks to 8 weeks when compared with the chemotherapy alone. Immunotherapy with SodA based DNA vaccine (DNAsod) reduced the pulmonary bacilli only as much as DNAvec. Both DNAacr and DNAsod, although significantly delayed the reactivation in comparison to the chemotherapy alone, this delay was associated with the immunostimulatory sequences present in the vector backbone and was not antigen specific. Both DNA vaccines resulted in the production of significantly higher number of TEM cells than the chemotherapy alone, however, only in the case of DNAsod, this enhancement was significant over the DNAvec treatment. Overall, our findings emphasize the immunotherapeutic potential of DNAacr in shortening the duration of TB chemotherapy.
authors: Department of Biochemistry, University of Delhi South Campus, New Delhi - 110021, India.
authors: Priyanka
authors: P
authors: Chauhan
authors: Ruchi
authors: R
authors: Jain
authors: Bappaditya
authors: B
authors: Dey
authors: Anil K
authors: AK
authors: Tyagi
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D018960:Hyaluronan Receptors / Q000378:metabolism; D007167:Immunotherapy; D019041:L-Selectin / Q000378:metabolism; D008168:Lung / Q000382:microbiology / Q000473:pathology; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D038201:alpha-Crystallins / Q000276:immunology*
chemical_list: D000995:Antitubercular Agents; D016207:Cytokines; D018960:Hyaluronan Receptors; D019444:Vaccines, DNA; D038201:alpha-Crystallins; D019041:L-Selectin
references: Expert Rev Vaccines. 2009 Sep;8(9):1237-50
references: 19722896
references: J Immunol. 2008 Oct 1;181(7):4955-64
references: 18802099
references: J Bacteriol. 1998 Feb;180(4):801-8
references: 9473032
references: Scand J Immunol. 2011 Jul;74(1):42-6
references: 21352251
references: PLoS One. 2012;7(7):e39215
references: 22844392
references: Nat Rev Immunol. 2008 Apr;8(4):247-58
references: 18323851
references: Eur J Immunol. 1999 Jun;29(6):1753-61
references: 10382737
references: Hum Vaccin. 2010 Apr;6(4):297-308
references: 20372079
references: J Immunol. 2009 Jun 15;182(12):8047-55
references: 19494330
references: Infect Immun. 1990 Jun;58(6):1937-42
references: 1692812
references: Nature. 1999 Jul 15;400(6741):269-71
references: 10421369
references: Infect Immun. 2000 May;68(5):2948-53
references: 10768993
references: J Immunol. 2005 Jul 15;175(2):633-9
references: 16002657
references: Vaccine. 2000 Nov 8;19(6):618-22
references: 11090712
references: Antimicrob Agents Chemother. 2006 Aug;50(8):2621-5
references: 16870750
references: Vaccine. 2006 Feb 20;24(8):1191-204
references: 16216394
references: Nat Med. 1996 Aug;2(8):893-8
references: 8705859
references: J Antimicrob Chemother. 2001 Jun;47(6):829-35
references: 11389115
references: Future Microbiol. 2006 Jun;1(1):63-73
references: 17661686
references: PLoS One. 2008;3(12):e3869
references: 19052643
references: Vaccine. 2000 Feb 25;18(16):1712-6
references: 10689154
references: Vaccine. 2005 Aug 31;23(37):4619-24
references: 16053938
references: Infect Immun. 1992 May;60(5):2066-74
references: 1563797
references: Clin Vaccine Immunol. 2010 Apr;17(4):618-25
references: 20107011
references: Chin Med J (Engl). 2006 Jul 5;119(13):1103-7
references: 16834929
references: Nat Med. 1996 Aug;2(8):888-92
references: 8705858
references: Clin Exp Immunol. 1992 Sep;89(3):395-401
references: 1381300
references: Microbiology (Reading). 1996 Jun;142 ( Pt 6):1375-1383
references: 8704977
references: Gene Ther. 2005 Feb;12(3):281-7
references: 15526006
references: Gene Ther. 2005 Apr;12(7):634-8
references: 15690060
references: Gene Ther. 2012 May;19(5):570-5
references: 21956689
references: Clin Exp Immunol. 1995 Oct;102(1):53-7
references: 7554399
references: Nature. 2011 Jan 27;469(7331):483-90
references: 21270886
references: Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7534-9
references: 11416222
references: Gene Ther. 2003 Sep;10(18):1592-9
references: 12907951
references: Nat Med. 2000 Dec;6(12):1327-9
references: 11100115
references: PLoS One. 2011;6(8):e23360
references: 21858087
references: J Infect Dis. 2013 Apr 15;207(8):1242-52
references: 22891286
references: PLoS One. 2011 Apr 18;6(4):e18773
references: 21533158
references: Scand J Immunol. 1998 Oct;48(4):403-9
references: 9790311
references: Infect Immun. 2004 Jan;72(1):381-8
references: 14688119
references: Nat Med. 2011 Feb;17(2):189-94
references: 21258338
references: Infect Immun. 2004 Apr;72(4):2412-5
references: 15039371
references: Vaccine. 2005 Dec 1;23(48-49):5655-65
references: 16157425
references: Lancet. 2011 Jul 2;378(9785):57-72
references: 21420161
references: Tuber Lung Dis. 1993 Dec;74(6):388-94
references: 8136492